Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Gazzard

Showing results (131-140 of 206) with videos related to

Pageof 21
Sort By:
Blood|November 8, 2003
Antibody-targeted MHC complex-directed expansion of HIV-1- and KSHV-specific CD8+ lymphocytes: a new approach to therapeutic vaccinationJustin Stebbing, Brian Gazzard, Steve Patterson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 20, 2011
Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individualsAkil Jackson, Victoria Watson, David Back, et al.
British Journal of Clinical Pharmacology|December 21, 2004
Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjectsMarta Boffito, David Back, Meredith Stainsby-Tron, et al.
Antiviral Therapy|July 21, 2004
Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimenMarta Boffito, Laura Dickinson, Andrew Hill, et al.
Antimicrobial Agents and Chemotherapy|May 22, 2013
Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokineticsGraeme Moyle, Laura Else, Akil Jackson, et al.
AIDS (London, England)|June 26, 2007
Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistanceMarta Boffito, Alan Winston, Akil Jackson, et al.
AIDS (London, England)|November 5, 2008
Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?Joanne Reekie, Amanda Mocroft, Helen Sambatakou, et al.
Genomics|April 1, 2010
Investigation of low-dose ritonavir on human peripheral blood mononuclear cells using gene expression whole genome microarraysSaliha Yilmaz, Marta Boffito, Sophie Collot-Teixeira, et al.
Antiviral Therapy|August 24, 2007
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patientsLauro J Waters, Graeme Moyle, Stefano Bonora, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 3, 2006
Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological responseAlan Winston, Nimesh Patel, David Back, et al.
Pageof 21

Showing results (131-140 of 206) with videos related to

Sort By:
Pageof 21
Blood|November 8, 2003
Antibody-targeted MHC complex-directed expansion of HIV-1- and KSHV-specific CD8+ lymphocytes: a new approach to therapeutic vaccinationJustin Stebbing, Brian Gazzard, Steve Patterson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 20, 2011
Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individualsAkil Jackson, Victoria Watson, David Back, et al.
British Journal of Clinical Pharmacology|December 21, 2004
Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjectsMarta Boffito, David Back, Meredith Stainsby-Tron, et al.
Antiviral Therapy|July 21, 2004
Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimenMarta Boffito, Laura Dickinson, Andrew Hill, et al.
Antimicrobial Agents and Chemotherapy|May 22, 2013
Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokineticsGraeme Moyle, Laura Else, Akil Jackson, et al.
AIDS (London, England)|June 26, 2007
Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistanceMarta Boffito, Alan Winston, Akil Jackson, et al.
AIDS (London, England)|November 5, 2008
Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?Joanne Reekie, Amanda Mocroft, Helen Sambatakou, et al.
Genomics|April 1, 2010
Investigation of low-dose ritonavir on human peripheral blood mononuclear cells using gene expression whole genome microarraysSaliha Yilmaz, Marta Boffito, Sophie Collot-Teixeira, et al.
Antiviral Therapy|August 24, 2007
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patientsLauro J Waters, Graeme Moyle, Stefano Bonora, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 3, 2006
Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological responseAlan Winston, Nimesh Patel, David Back, et al.
Pageof 21